Search filters

List of works by Steven P. Treon

A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader.

scientific article published on 7 November 2017

A Novel Functional Role for Soluble CD27 in the Pathogenesis of Waldenstrom’s Macroglobulinemia. ⬇️

scholarly article

A Novel HCK Inhibitor Kin-8193 Blocks BTK Activity in BTKCys481 Mutated Ibrutinib Resistant B-Cell Lymphomas Driven By Mutated MYD88 ⬇️

scholarly article

A SCID-hu in vivo model of human Waldenström macroglobulinemia

scientific article published on 10 May 2005

A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia

scientific article published on 29 January 2020

A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.

scientific article published on 8 July 2013

A new era for Waldenstrom macroglobulinemia: MYD88 L265P ⬇️

scientific article published on May 30, 2013

A prognostic index predicting survival in transformed Waldenström macroglobulinemia

scientific article published on 12 November 2020

Aberrant DNA Methylation and Transcriptional Silencing of DLC-1 in Waldenstrom's Macroglobulinemia. ⬇️

scholarly article

Aberrant Expression of Regulatory miRNAs and Transcripts for IRS-PI3K Growth and Survival Signaling In Waldenstrom's Macroglobulinemia ⬇️

scholarly article

Abnormal Expression of TRAF Adapter Proteins in Waldenstrom’s Macroglobulinemia. ⬇️

scholarly article

Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.

scientific article published on 24 February 2017

Acquisition of BTK C481S Produces Resistance to Ibrutinib in MYD88 Mutated WM and ABC DLBCL Cells That Is Accompanied By ERK1/2 Hyperactivation, and Is Targeted By the Addition of the ERK1/2 Inhibitor Ulixertinib ⬇️

scholarly article

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

scientific article published in August 2002

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications

scientific article published in December 2001

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications

scientific article published on 12 August 2011

Advances in the biology and treatment of Waldenström's macroglobulinemia: a report from the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden

scientific article published on 01 March 2009

Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias.

scientific article published in September 2008

Amyloidosis and Waldenström's macroglobulinemia

scientific article

Analysis of Chemokine and Adhesion Markers in Waldenstrom Macroglobulinemia. ⬇️

scholarly article

Anti-estrogens induce apoptosis of multiple myeloma cells

scientific article published on 01 September 1998

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

scientific article published in June 2002

Associated Malignancies Among Patients and Kin with Waldenstrom's Macroglobulinemia ⬇️

scholarly article

Associated malignancies in patients with Waldenström's macroglobulinemia and their kin.

scientific article

Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia

scientific article published on 28 April 2016

Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia

scientific article (publication date: July 2011)

BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism.

scientific article

Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy

scientific article published on 01 March 2009

Bendamustine Therapy in Patients With Relapsed or Refractory Waldenström's Macroglobulinemia ⬇️

scientific article published on 01 February 2011

Bendamustine-Based Therapy Is Highly Active In Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia ⬇️

scholarly article

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

scientific article

Biology, prognosis, and therapy of Waldenström Macroglobulinemia

scientific article published on January 2015

Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells

scientific article published on 01 June 1997

Bone Marrow Niche Down-Regulates Mir-30 In Multiple Myeloma Cells to Promote Cancer Progression and Cancer Initiation by Targeting BCL9/Wnt Pathway. ⬇️

scholarly article

Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences.

scientific article

Bortezomib as a treatment option in patients with Waldenström macroglobulinemia

scientific article published on April 2010

Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom's Macroglobulinemia patients

scientific article published on 26 October 2018

Bortezomib, Dexamethasone and Rituximab (BDR) Is a Highly Active Regimen in the Primary Therapy of Waldenstrom’s Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-180. ⬇️

scholarly article

Bruton tyrosine kinase degradation as a therapeutic strategy for cancer

scientific article published on 13 December 2018

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

scientific article

CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia

scientific article published in May 2001

CD20-Directed Serotherapy in Patients With Multiple Myeloma: Biologic Considerations and Therapeutic Applications

scientific article published on 01 January 2002

CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia

scientific article published on 01 May 2001

CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia.

scientific article published on 23 January 2008

CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines.

scientific article published on February 2000

CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling

scientific article published on 14 November 2002

CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia

scientific article published on 01 March 2005

CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders

scientific article published on May 2006

CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia.

scientific article

CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib.

scientific article published on 10 August 2017

CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia

scientific article published on 01 October 2019

CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells

scientific article published on 05 November 2014

CXCR4 in Waldenström's Macroglobulinema: chances and challenges

scientific article published on 03 December 2020

CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib

scientific article published on 03 July 2019

CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors

scientific article published on 13 January 2020

CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review

scientific article published on 30 July 2019

Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia

scientific article published on 23 May 2014

Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.

scientific article

Challenges With Serum Protein Electrophoresis in Assessing Progression and Clinical Response in Patients With Waldenström Macroglobulinemia ⬇️

scientific article published on April 1, 2013

Characterization of familial Waldenstrom's macroglobulinemia

scientific article published on 15 December 2005

Characterization of p16(INK4A) expression in multiple myeloma and plasma cell leukemia

scientific article published on 01 November 1997

Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6.

scientific article

Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia

scientific article published on 10 March 2008

Clinical responses to sildenafil in Waldenstrom's macroglobulinemia.

scientific article published in December 2004

Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

scientific article

Clonal B cells in Waldenström's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling

scientific article published on 12 February 2016

Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia

scientific article

Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia

Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood

scientific article published on 5 February 2004

Comparative Effectiveness of Rituximab-Based Immunochemotherapy in Waldenstrom's Macroglobulinemia (WM) ⬇️

scholarly article

Comparative Response Assessment by Serum Immunoglobulin M M-Protein and Total Serum Immunoglobulin M After Treatment of Patients With Waldenström Macroglobulinemia ⬇️

scientific article published on April 1, 2013

Comparative genomics of CXCR4MUT and CXCR4WT single cells in Waldenström's macroglobulinemia

scientific article published on 01 September 2020

Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia.

scientific article

Comparative outcomes of immunochemotherapy regimens in Waldenström macroglobulinaemia.

scientific article

Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia

scientific article

Comprehensive Assessment of Cytokines and Chemokines In Patients with Waldenstrom's Macroglobulinemia Reveals a Distinct Profile with Pathobiological and Clinical Relevance ⬇️

scholarly article

Conflicts of interest, authorship, and disclosures in industry-related scientific publications

scientific article

Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic

scientific article published on 30 July 2020

Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia

scientific article published on 01 November 2020

Correction: Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström Macroglobulinemia

scientific article published on 01 August 2019

Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia

scientific article published on 10 May 2015

Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia

scientific article published on 23 December 2019

Defining Waldenstrom's macroglobulinemia

scientific article published in April 2003

Defining the Incidence, Pathology and Clinical Outcomes of Kidney Disease Related to Waldenstrom's Macroglobulinemia and IgM MGUS ⬇️

scholarly article

Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells.

scientific article

Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance

scientific article published on 10 February 2014

Diagnosis and management of Waldenstrom's macroglobulinemia

scientific article (publication date: March 2005)

Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma

scientific article published on 09 October 2020

Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma

scientific article published on 17 March 2014

Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.

scientific article published on 10 June 2016

Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia

scientific article published on 11 September 2018

Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia

scientific article published on 3 March 2008

Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom's macroglobulinemia

scientific article published in March 2008

Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma

scientific article

Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma

scientific article published on 01 November 2000

Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia.

scientific article

Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition

scientific article published on 24 December 2020

Epigenomics in Waldenstrom's macroglobulinaemia

scientific article published on June 2016

Epigenomics in Waldenström macroglobulinemia

scientific article published on 01 July 2020

Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice.

scientific article published on September 2007

Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis.

scientific article

Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia.

scientific article published on 22 February 2016

Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia

scientific article published on 06 February 2009

Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations

scientific article (publication date: April 2003)

Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas

scientific article published on 01 January 2020

Extended rituximab therapy in Waldenström's macroglobulinemia.

scientific article published in January 2005

Extracellular vesicle-mediated transfer of constitutively active MyD88L265P engages MyD88wt and activates signaling

scientific article published on 22 January 2018

Extramedullary Waldenström macroglobulinemia

scientific article published on 19 November 2014

Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia

scientific article published on 17 October 2012

Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: a preliminary study

scientific article published on 17 November 2011

Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia ⬇️

scholarly article

Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia

scientific article published in February 2018

Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications

scientific article published on 01 October 2003

Future therapeutic options for patients with Waldenström macroglobulinemia

scientific article published on June 2016

Gene Expression Profiling Distinguishes Waldenstrom's Macroglobulinemia Patients Presenting with Familial Disease, Advanced IPSS Prognostic Score, and Previous Treatment with Rituximab. ⬇️

scholarly article

Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy

scientific article published on 01 January 2007

Genomic Analysis of Ibrutinib Resistance in Waldenstrom Macroglobulinemia ⬇️

scholarly article

Genomic Landscape of Waldenström Macroglobulinemia

scientific article published on 25 July 2018

Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies

scientific article published on 21 February 2020

Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia

scientific article published on 27 February 2020

Genomic profiling for clinical decision making in lymphoid neoplasms

Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.

scientific article published on 13 February 2017

Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome

scientific article

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.

scientific article published on 3 May 2016

Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia.

scientific article published in January 2007

Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenström's macroglobulinemia

scientific article published on 01 February 2011

Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)

scientific article published on 01 December 2006

Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia

scientific article published on 14 July 2016

Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenström's Macroglobulinemia ⬇️

scientific article published on February 1, 2011

How we manage Bing-Neel syndrome

scientific article published on 20 August 2019

Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells

scientific article published on 01 November 2019

Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia

scientific article published on 10 January 2011

Hyperviscosity-related retinopathy in waldenstrom macroglobulinemia.

scientific article

IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade.

scientific article published on September 1997

Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia

scientific article published on 25 July 2018

Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia

scientific article published on 3 December 2015

Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound.

scientific article published on 27 December 2017

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

scientific article

Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study

scientific article published on 06 December 2018

Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience

scientific article

Ibrutinib in previously treated Waldenström's macroglobulinemia.

scientific article

Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome.

scientific article published on 13 July 2016

Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia.

scientific article published on 22 February 2018

Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity

scientific article published on 26 August 2016

IgA and IgG Hypogammaglobulinemia Are Associated with Mutations in the APRIL/BLYS Receptor TACI in Waldenstrom’s Macroglobulinemia (WM). ⬇️

scholarly article

IgA and IgG Hypogammaglobulinemia Does Not Predict for Recurrent Infection Risk and Persists Despite Therapeutic Response in Patients with Waldentrom's Macroglobulinemia. ⬇️

scholarly article

IgA and IgG Hypogammaglobulinemia Is a Constitutive Feature in Most Waldenstrom’s Macroglobulinemia Patients and May Be Related to Mutations Associated with Common Variable Immunodeficiency Disorder (CVID) ⬇️

scholarly article

IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia.

scientific article

Immunogenicity of recurrent mutations in MYD88 and EZH2 in non-Hodgkin lymphomas.

scientific article published on 4 November 2015

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

scientific article published on December 2005

Immunotherapeutic strategies for the treatment of plasma cell malignancies

scientific article

Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia

scholarly article by Jorge J Castillo et al published October 2018 in Haematologica

Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis

scientific article published on 02 December 2018

Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database.

scientific article

Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs

scientific article published on 8 December 2008

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism

scientific article

Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders

article

Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia

scientific article published on 24 September 2008

Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders

scientific article published on January 2016

Initial Evaluation of the Patient with Waldenström Macroglobulinemia

scientific article published on 23 July 2018

Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia

scientific article published on 01 November 2018

Inter and Intra-Clonal Heterogeneity in Multiple Myeloma and Waldenstrom Macroglobulinemia ⬇️

scholarly article

Interleukin-17 and TH17 Pathway Supports Waldenstrom's Macroglobulinemia Cell-Growth: Potential Therapeutic Implications ⬇️

scholarly article

Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells

scientific article published on 01 July 1997

International prognostic scoring system for Waldenstrom macroglobulinemia

scientific article published on 5 February 2009

Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells

scientific article published in March 2002

Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel

scientific article published on 15 February 2017

Involvement of Lipogenic Pathway In 5-Azacytidine-Induced Cytotoxicity In Waldenstrom's Macroglobulinemia ⬇️

scholarly article

Isolation and characterization of human multiple myeloma cell enriched populations

scientific article published on 01 February 2000

Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up

scientific article published on 01 August 2020

Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis

scientific article

Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage

scientific article published on 01 December 2000

Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.

scientific article

Long survival in patients with Waldenström macroglobulinaemia diagnosed at a young age

scientific article published on 08 November 2018

Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia

scientific article published on 15 September 2020

Long-Term Outcome of a Prospective Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously Untreated, Symptomatic Patients with Waldenstrom's Macroglobulinemia ⬇️

scholarly article

Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab

scientific article

Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia

scientific article

Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia

scientific article

Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia

scientific article published on 13 March 2018

Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib

scientific article published on 20 November 2018

MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells ⬇️

scientific article published on September 1, 1997

MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction ⬇️

scientific article published on January 15, 2013

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

scientific article

MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia

scientific article published on 01 August 2015

MYD88 Triggered SYK Activation Promotes BCR Cross-Talk, and Identifies SYK As a Novel Therapeutic Target of Mutated MYD88 Signaling ⬇️

scholarly article

MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinaemia.

scientific article

MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival

scientific article published on 27 November 2017

MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia.

scientific article published on 12 March 2014

Maintenance Rituximab Is Associated with Improved Progression Free and Overall Survival in Waldenstrom's Macroglobulinemia. ⬇️

scholarly article

Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen

scientific article published on 25 May 2011

Management of Waldenström macroglobulinemia in 2020

scientific article published on 01 December 2020

Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma

scientific article published on 28 April 2017

Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling

scientific article published on 20 June 2006

Matrix metalloproteinase-8 is overexpressed in Waldenström's macroglobulinemia cells, and specific inhibition of this metalloproteinase blocks release of soluble CD27

scientific article published on 01 February 2011

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

scientific article published on April 2004

Micro-RNA Expression Profiling Reveals Distinct Correlates to Disease Pathogenesis, and Identifies Novel Pathways Involved in Tumor Cell Senescence and IL-12A Signaling. ⬇️

scholarly article

Microarray Analysis of the Peripheral Monocytes From Waldenstrom's Macroglobulinemia Patients Reveals a Distinct Gene Expression Profile ⬇️

scholarly article

Molecular Mechanisms Regulating Resistance to the Akt Inhibitor Perifosine in Waldenstrom’s Macroglobulinemia, the Role of the ERK and PKC Pathways. ⬇️

scholarly article

Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.

scientific article published on 12 January 2012

Molecular characterization of Waldenstrom's macroglobulinemia reveals frequent occurrence of two B-cell clones having distinct IgH VDJ sequences

scientific article published on April 2007

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

scientific article

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

scientific article

Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone.

scientific article published on February 1999

Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.

scientific article

Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia

scientific article published on 01 October 2020

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology

scientific article published on November 2015

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

scientific article published on February 2017

Multiple myeloma

scientific article published on 01 October 2011

Multiple myeloma, version 1.2013.

scientific article published in January 2013

Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenstrom's Macroglobulinemia ⬇️

scholarly article

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

scientific article

Next Generation Sequencing Identifies a Distinct Transcriptional Profile, Including Isoform Dysregulation That Segue with Genomic Alterations in Waldenstrom's Macoglobulinemia ⬇️

scholarly article

Non-IgM Secreting Lymphoplasmacytic Lymphoma - Experience of a Reference Center for Waldenstrom Macroglobulinemia ⬇️

scholarly article

Novel Agent Perifosine Enhances Antitumor Activity of Bortezomib, Rituximab and Other Conventional Therapies in Waldenstrom’s Macroglobulinemia. ⬇️

scholarly article

Novel agents in the treatment of Waldenström's macroglobulinemia.

scientific article published on August 2007

Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.

scientific article

Novel biologically based therapies for Waldenstrom's macroglobulinemia

scientific article

Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenström's macroglobulinemia

scientific article

Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database

scientific article published on 18 December 2014

Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia

scientific article published on 01 October 2004

Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib

scientific article published on 18 November 2020

Patients with Waldenstrom's Macroglobulinemia Are Often Hypoferremic That Is Refractory to Oral Iron Repletion and Responsive to Parental Iron Infusions, and Demonstrate Elevated Levels of Hepcidin. ⬇️

scholarly article

Patients with Waldenström macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administration

scientific article published on 22 March 2013

Perifosine, an Oral Bioactive Novel Akt Inhibitor, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom Macroglobulinemia. ⬇️

scholarly article

Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia

scientific article published on 01 June 2018

Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia

scientific article published on 03 July 2015

Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia ⬇️

scholarly article

Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia

scientific article

Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia

scientific article

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia

scientific article

Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia

scientific article published in January 2005

Potential impact of a single nucleotide polymorphism in the hyaluronan synthase 1 gene in Waldenstrom's macroglobulinemia

scientific article published in March 2005

Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.

scientific article

Proceedings of the Seventh International Workshop on Waldenström Macroglobulinemia ⬇️

scientific article published on April 1, 2013

Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia

scientific article published in PLoS ONE

Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

scientific article (publication date: April 2003)

Progression Free Survival Is Predicated by Categorical Response, and Supports the Attainment of VGPR/CR as An Objective for Long Term Disease Control in Waldenstrom's Macroglobulinemia. ⬇️

scholarly article

Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia

scientific article published on 16 April 2019

Prospective clinical trial of ixazomib, dexamethasone and rituximab as primary therapy in Waldenström macroglobulinemia.

scientific article published on 16 April 2018

Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214).

scientific article published on 11 November 2016

Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia ⬇️

scholarly article

Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia

scientific article published on 06 February 2007

Proteomic Analysis of Waldenstrom Macroglobulinemia

article

Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias ⬇️

scientific article published on 01 April 2003

Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells

scientific article published on 01 May 2003

Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia

scientific article published on 05 July 2016

Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes

scientific article published on 29 July 2016

Reply to F.D. Leonard

scientific article published on 19 August 2019

Report from the Sixth International Workshop on Waldenström's Macroglobulinemia

scientific article published in February 2011

Report of the Third International Workshop on Waldenstrom's macroglobulinemia

scientific article published on 01 March 2005

Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials

scientific article published on 21 May 2020

Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia

scientific article published on 22 February 2018

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop

scientific article

Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation

scientific article published on 16 March 2016

Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia

scientific article

Rituximab intolerance in patients with Waldenström macroglobulinaemia

scientific article published on 02 November 2015

Role of CDK4 and p16INK4A in interleukin-6-mediated growth of multiple myeloma

scientific article published on 01 November 1997

SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas

scientific article published on 31 January 2020

Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia

scientific article

Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia

scientific article published on 01 June 2008

Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia

scientific article published in March 2009

Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia

scientific article published on 19 February 2014

Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications

scientific article published on 29 June 2006

Spotting the elusive Siberian tiger: Complete response to ibrutinib in a patient with Waldenström Macroglobulinemia

scientific article published on 14 May 2018

Survival outcomes of secondary cancers in patients with Waldenström macroglobulinemia: An analysis of the SEER database.

scientific article published on 28 May 2015

Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database.

scientific article

TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia

scientific article published on 05 September 2018

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

scientific article published in August 2001

Targeting IRAK1/IRAK4 Signaling in Waldenstrom's Macroglobulinemia ⬇️

scholarly article

Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia

scientific article published on 13 April 2016

Targeting Myddosome Self-Assembly in Waldenstrom's Macroglobulinemia ⬇️

scholarly article

Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191

scientific article published on 20 August 2018

Targeting NF-kappaB in Waldenstrom macroglobulinemia

scientific article

Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia

scientific article published on 6 March 2015

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

scientific article published in July 2001

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.

scientific article published in November 2000

Thalidomide and rituximab in Waldenstrom macroglobulinemia

scientific article

The 86-kD subunit of Ku autoantigen mediates homotypic and heterotypic adhesion of multiple myeloma cells ⬇️

scientific article published on March 15, 1998

The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia

scientific article (publication date: 15 December 2007)

The Anti-CD20 Monoclonal Antibody GA101 Displays More Robust Anti-Tumor Activity Versus Rituximab In Waldenstrom's Macroglobulinemia (WM) ⬇️

scholarly article

The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells

scientific article published on 12 January 2015

The BTK-inhibitor ibrutinib may protect against pulmonary injury in COVID-19 infected patients

scientific article published on 17 April 2020

The CXCR4/SDF-1 Axis Regulates Migration and Adhesion in Waldenstrom Macroglobulinemia. ⬇️

scholarly article

The Clonal Architecture of CXCR4mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability ⬇️

scholarly article

The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells.

scientific article

The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia

scientific article published on 3 June 2008

The IgM Flare Following Rituximab and IVIG Administration in Waldenstrom's Macroglobulinemia Is Related to IL-6 Production by Bystander Immune Cells, Possibly through Stimulation of the Fcgriia Receptor. ⬇️

scholarly article

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

The Proteasome Inhibitor NPI-0052 in Combination with Bortezomib Induces Antitumor Activity in Waldenstrom Macroglobulinemia. ⬇️

scholarly article

The Role of Bortezomib-Containing Regimens in Improving Response in Patients with Waldenstrom Macroglobulinemia ⬇️

scholarly article

The Selective Protein Kinase CB Inhibitor, Enzastaurin, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom’s Macroglobulinemia. ⬇️

scholarly article

The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.

scientific article

The development of a model for the homing of multiple myeloma cells to human bone marrow

scientific article published on 01 July 1997

The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis

scientific article

The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions

scientific article

The malignant clone in Waldenstrom's macroglobulinemia ⬇️

scientific article published on April 1, 2003

The race to stymie BTK: zanu zings

scientific article published on 01 October 2020

The real world of Waldenström's macroglobulinaemia

scientific article published on 01 July 2018

To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenström Macroglobulinaemia.

scientific article published on 2 March 2016

Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells

scientific article published on 02 December 2015

Toward personalized treatment in Waldenström macroglobulinemia.

scientific article published in December 2017

Transcriptional repression of plasma cell differentiation is orchestrated by aberrant over-expression of the ETS factor SPIB in Waldenström macroglobulinaemia

scientific article published on 07 May 2014

Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.

scientific article published on 14 June 2016

Treatment Recommendations in Waldenström Macroglobulinemia

Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens.

scientific article

Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy

scientific article published on 01 October 1999

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus

scientific article

Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia

scientific article published on 18 July 2016

Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

scientific article

Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies.

scientific article published in May 2001

Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.

scientific article published in May 2001

Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma

scientific article published on 01 May 2004

Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

scientific article

Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia

scientific article

Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia

scientific article published on December 2008

Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia

scientific article published on 12 January 2006

Venetoclax in Previously Treated Waldenström Macroglobulinemia

Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells.

scientific article published on 10 June 2011

Waldenstrom's macrogloblinemia/ lymphoplasmacytic lymphoma

scientific article published on January 2008

Waldenström Macroglobulinemia

scientific article published on 05 August 2014

Waldenström Macroglobulinemia: Lessons Learned from Basic and Clinical Research

scientific article published on 01 October 2018

Waldenström macroglobulinemia: from biology to treatment

scientific article published on 03 January 2014

Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.

scientific article published in October 2012

What is new in the treatment of Waldenstrom macroglobulinemia?

scientific article published on 07 October 2019

Whole Genome Sequencing Reveals a Widely Expressed Mutation (MYD88 L265P) with Oncogenic Activity in Waldenstrom's Macroglobulinemia ⬇️

scholarly article

Whole Genome and Transcriptome Analysis of Waldenstrom's Cell Lines Show Preservation of Many Important Genomic Features of Primary Disease, and Identify a Non-L265P Mutation in MYD88 ⬇️

scholarly article

miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth.

scientific article

miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway

scientific article

microRNA aberrations in Waldenström macroglobulinemia

scientific article published on 07 March 2013

mutated and wild-type Waldenström's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in

article

p16INK4A promotes differentiation and inhibits apoptosis of JKB acute lymphoblastic leukemia cells.

scientific article published on November 1997

Paulina is supported by:

About Paulina

Help